Incidence of dementia
=====================

Alzheimer's disease (AD) is the most common cause of dementia, comprising 50%--70% of all cases and affecting more than 15 million people worldwide. Frontotemporal dementia (FTD), in comparison, is less common but may make up to 50% of dementia cases presenting before the age of 60 ([@b56-ndt-4-1033]). Dementia is defined as the significant loss of intellectual abilities such as memory functions, severe enough to interfere with social or occupational functioning. At present, AD cannot be cured which is different from memory dysfunction caused by malnutrition, drug abuse or depression where some form of treatment is available ([@b95-ndt-4-1033]).

Neuropathology of AD and FTD
============================

The AD brain is characterized by massive neuronal cell and synapse loss at specific predilection sites ([@b110-ndt-4-1033]). The extracellular plaques and the intracellular neurofibrillary tangles are the key histopathological hallmarks of AD. The major proteinaceous component of the amyloid plaques is a 40- to 42-amino acid polypeptide termed Aβ (Aβ~40~ and Aβ~42~), which is derived by proteolytic cleavage from the amyloid precursor protein, APP, as part of normal cellular metabolism ([@b41-ndt-4-1033]; [@b89-ndt-4-1033]). β-Secretase is the protease that generates the amino terminus of Aβ and γ-secretase cleavage at the carboxy-terminus dictates its length. Aβ~40~ is the most common species and Aβ~42~ is the more fibrillogenic and neurotoxic species. Recent evidence suggests that Aβ~40~ may prevent Aβ~42~ from aggregating and forming plaques ([@b135-ndt-4-1033]). β-Secretase activity has been attributed to a single protein, BACE 1 ([@b124-ndt-4-1033]), whereas γ-secretase activity depends on four components, presenilin, nicastrin, APH-1 and PEN-2 forming a proteolytic complex ([@b38-ndt-4-1033]). α-Secretase is involved in the non-amyloidogenic pathway by cleaving APP within the Aβ domain, thus precluding Aβ formation ([@b48-ndt-4-1033]). Which higher order forms of Aβ exert toxicity is a matter of debate. The conflicting data as well as putative mechanisms of toxicity are discussed in detail below.

The second histopathological hallmark of AD are the neurofibrillary lesions that are found in cell bodies and apical dendrites as neurofibrillary tangles, in distal dendrites as neuropil threads, and in the abnormal neurites that are associated with some β-amyloid plaques (neuritic plaques). Neurofibrillary tangles are also abundant, in the absence of overt plaques, in FTD and other so-called tauopathies ([@b82-ndt-4-1033]). The neurofibrillary lesions contain aggregates of the microtubule-associated protein tau that under physiological conditions is mainly localized to the axonal compartment of neurons ([@b42-ndt-4-1033]). In tauopathies such as PSP (Progressive Supranuclear Palsy) or CBD (Corticobasal Degeneration), tau also forms aggregates in non-neuronal cells ([@b44-ndt-4-1033]), emphasizing the important role of glia in disease ([@b78-ndt-4-1033]). Tau has an unusually high content of serine and threonine residues and many of these are phosphorylated under physiological conditions ([@b19-ndt-4-1033]). Under pathological conditions, tau is hyperphosphorylated, which means that it is phosphorylated to a higher degree at physiological sites, and at additional "pathological" sites. Phosphorylation tends to dissociate tau from microtubules. Tau also undergoes a conformational change which likely assists in differential phosphorylation ([@b72-ndt-4-1033]). Both tau and Aβ undergo nucleation-dependent fibril formation ([@b59-ndt-4-1033]). In the course of this process, initially dispersed polypeptide chains slowly come together to form a diverse array of fibrillation nuclei that enable the rapid outgrowth into higher order assemblies including fibrils ([@b65-ndt-4-1033]; [@b96-ndt-4-1033]; [@b49-ndt-4-1033]).

Genetics of AD and FTD
======================

In familial AD, autosomal dominant mutations have been identified in three genes: APP and the presenilin 1 (PS1) and presenilin 2 (PS2) genes. Together, they account for less than 1% of the total number of AD cases ([@b32-ndt-4-1033]). In addition, several susceptibility genes have been identified but only the apolipoprotein E (APOE) gene has been unanimously confirmed and found to be associated with sporadic AD ([@b109-ndt-4-1033]). Clinically and histopathologically, early-onset familial AD cannot be discriminated from late-onset sporadic AD ([@b44-ndt-4-1033]).

Whereas in AD no mutations were found in the MAPT gene encoding tau, they were identified in FTD with Parkinsonism linked to chromosome 17 (FTDP-17) ([@b67-ndt-4-1033]; [@b105-ndt-4-1033]; [@b117-ndt-4-1033]). This established that dysfunction of tau in itself can cause neurodegeneration and lead to dementia. The existence of a subgroup of FTD with no tau aggregation was enigmatic for some time leading to the coining of terms such as 'dementia lacking distinctive histology'. This dementia with tau-negative and ubiquitin-positive lesions today is termed FTLD-U or FTDU-17 although this is misleading as it implies that the tau lesions in FTDP-17 are ubiquitin-negative which is not the case.

FTDU-17 is caused by loss-of-function mutations in the gene encoding progranulin (PGRN), a growth factor involved in multiple physiological and pathological processes including tumorigenesis ([@b8-ndt-4-1033]; [@b26-ndt-4-1033]). The TAR DNA-binding protein of 43 kDa (TDP-43) is a constituent of the ubiquitin-positive inclusions in both FTLD-U and sporadic amyotrophic lateral sclerosis (ALS) arguing for an overlap in the pathology between these two entities ([@b94-ndt-4-1033]). Similar to tau, in diseased brain, TDP-43 becomes hyperphosphorylated, ubiquitinated, and carboxy-terminally truncated. Mutations in the gene encoding valosin-containing protein cause frontotemporal dementia with inclusion body myopathy and Paget disease of bone (IBMPFD), a rare, autosomal-dominant disorder. As TDP-43, but not valosin-containing protein, is accumulating in the ubiquitin-positive inclusions in IBMPFD this would argue that valosin-containing protein gene mutations lead to a dominant negative loss or alteration of valosin-containing protein function culminating in impaired degradation of TDP-43. In other words, TDP-43 is a common pathologic substrate linking a variety of distinct patterns of FTLD-U pathology caused by different genetic alterations ([@b93-ndt-4-1033]).

Clinical features of AD and FTD
===============================

AD is characterized by early memory deficits, followed by a gradual erosion of other cognitive functions such as judgment, verbal fluency and orientation. The most severe neuropathological changes occur in the hippocampal formation, followed by the association cortices and subcortical structures, including the amygdala and the nucleus basalis of Meynert ([@b7-ndt-4-1033]). Neurofibrillary tangles develop and spread in a predictable manner across the brain providing the basis for distinguishing six stages of disease progression: the transentorhinal Braak stages I--II represent clinically silent cases; the limbic stages III--IV incipient AD; and the neocortical stages V--VI fully developed AD. By using phosphorylation-dependent anti-tau antibodies such as AT8, neuronal changes can be visualized well before the actual formation of neurofibrillary tangles ([@b13-ndt-4-1033], [@b14-ndt-4-1033]).

In contrast to AD, which is characterized predominantly by memory loss, FTD is mainly initiated with behavioral impairment. The average age of diagnosis is about 60, which is around 10 years before the average sporadic AD patient is diagnosed ([@b114-ndt-4-1033]; [@b129-ndt-4-1033]). Patients may have an often asymmetrical atrophy of the frontal and temporal cortex. There is evidence that motor neuron disease and FTD coexist, and the motor symptoms may precede, coincide, or follow the development of cognitive and behavioral changes ([@b56-ndt-4-1033]). In a significant subset of FTD, late parkinsonism is found ([@b82-ndt-4-1033]).

Animal models of AD and FTD
===========================

To better understand the role of Aβ and tau in AD and related disorders, experimental animal models have been developed which reproduce aspects of the neuropathological characteristics of these diseases ([@b47-ndt-4-1033]; [@b48-ndt-4-1033]).

In 1995, Games and coworkers established the first Aβ plaque-forming mouse model by targeting high levels of the disease-linked V717F mutant form of APP in brain, using the platelet-derived growth factor mini-promoter for expression. These PDAPP mice showed many of the pathological features of AD, including extensive deposition of extracellular amyloid plaques, astrocytosis and neuritic dystrophy ([@b40-ndt-4-1033]). Similar features were observed in a second transgenic model established by Hsiao and coworkers by expressing the APP^sw^ mutation inserted into a hamster prion protein cosmid vector ([@b66-ndt-4-1033]). The APP23 strain was established by expressing APP^sw^ under the control of the neuronal mThy1.2 promoter, with a seven-fold overexpression of APP ([@b121-ndt-4-1033]; [@b119-ndt-4-1033]). Subsequently, many more models have been developed such as the TgCRND8 or J20 mice ([@b71-ndt-4-1033]; [@b91-ndt-4-1033]). These mouse models have been instrumental in addressing aspects of Aβ toxicity and testing therapies such as vaccination trials ([@b44-ndt-4-1033]; [@b54-ndt-4-1033]; [@b77-ndt-4-1033]).

The first tau transgenic model was established by us in 1995, expressing the longest human brain tau isoform, without a pathogenic mutation, in mice using the hThy1 promoter for neuronal expression ([@b52-ndt-4-1033]). Despite the lack of a neurofibrillary pathology, these mice modeled aspects of human AD, such as the somatodendritic localization of hyperphosphorylated tau and, therefore, represented an early 'pre-tangle' phenotype. The subsequent use of stronger promoters caused a more pronounced tau phenotype in transgenic mice ([@b68-ndt-4-1033]; [@b118-ndt-4-1033]; [@b106-ndt-4-1033]; [@b51-ndt-4-1033]). Once the first pathogenic FTDP-17 mutations were identified in the MAPT gene in 1998, several groups expressed them in mice and achieved neurofibrillary tangle formation, both in neurons and in glial cells ([@b48-ndt-4-1033]). We, for example, expressed G272V and P301L mutant tau and obtained mice with aggregated tau and neurofibrillary tangles ([@b45-ndt-4-1033]; [@b44-ndt-4-1033]; [@b44-ndt-4-1033]; [@b34-ndt-4-1033]). The P301L tau-expressing pR5 mice showed a behavioural impairment in amygdala- and hippocampus-dependent tasks; aspects of the behavioral impairment could be correlated with the aggregation pattern of the transgene ([@b98-ndt-4-1033]; [@b99-ndt-4-1033]). K369I transgenic mice, on the other hand, model Parkinsonism in FTD, in parts owing to expression of the transgene in the substantia nigra ([@b69-ndt-4-1033]).

Cross-talk between Aβ and tau
=============================

The amyloid cascade hypothesis claims, in simplistic terms, that in the pathogenic cascade of AD, Aβ is upstream of tau ([@b58-ndt-4-1033]). To address the interaction between Aβ and tau ([@b53-ndt-4-1033]), Aβ plaque-forming Tg2576 mice were crossed with tangle-forming P301L tau-transgenic JNPL3 mice; also, P301L tau transgenic pR5 mice were intracerebrally injected with fibrillar preparations of Aβ~42~ ([@b46-ndt-4-1033]; [@b84-ndt-4-1033]). Both strategies caused an increased tau phosphorylation at pathological epitopes and neurofibrillary tangle formation, establishing a link between Aβ and tau in vivo ([@b46-ndt-4-1033]; [@b84-ndt-4-1033]). Similarly, tangle formation was aggravated by infusing brain extracts of aged plaque-forming APP23 mice intracerebrally in P301L tau transgenic mice or by crossing APP23 and P301L tau transgenic mice ([@b12-ndt-4-1033]). Together, these studies established that Aβ exaggerates a pre-existing tau pathology supporting, at least in parts, the amyloid cascade hypothesis in mice.

Interestingly, recent evidence suggests that Aβ toxicity is also tau-dependent ([@b108-ndt-4-1033]). Reducing endogenous tau levels prevented behavioral deficits as assessed in the Morris water maze, without altering Aβ levels. This was achieved by crossing plaque-forming APP transgenic mice onto hetero- and homozygous tau knockout backgrounds ([@b108-ndt-4-1033]). Tau reduction also protected both transgenic and non-transgenic mice against pentylenetetrazole (PTZ)-mediated excitotoxicity as shown by dramatic changes in seizure severity and latency. We were able to reproduce these findings in a second plaque-forming APP transgenic mouse model (Ittner et al submitted). Earlier findings in cultured hippocampal neurons derived from tau knockout and transgenic mice supports the model that tau is required for Aβ toxicity ([@b107-ndt-4-1033]). Together, this suggests that a reduction in tau levels is a potentially powerful treatment strategy for AD and other neurological conditions that are associated with neurotoxicity. A mechanistic explanation is lacking and therefore the importance of this information should encourage more research groups to work on the interaction between Aβ and tau.

Functional genomics and Aβ toxicity
===================================

An unbiased approach to address the toxicity of tau and Aβ is by functional genomics, which encompasses transcriptomic and proteomic techniques ([@b20-ndt-4-1033]; [@b63-ndt-4-1033]; [@b27-ndt-4-1033]; [@b61-ndt-4-1033]). These highlighted a role for oxidative stress (see below) and impaired axonal transport in disease ([@b50-ndt-4-1033]). When we analyzed the proteome pattern of total brain from P301L tau transgenic pR5 and wild-type mice by proteomics, we discovered that it was mainly metabolic related proteins including mitochondrial respiratory chain complex components, antioxidant enzymes and synaptic proteins that were modified in P301L tau mice. Importantly, mitochondrial dysfunction could be functionally validated in the P301L tau mice. Furthermore, the reduction in mitochondrial complex V levels in the P301L tau mice was also decreased in human P301L FTDP-17 brains. Finally, P301L tau mitochondria displayed an increased vulnerability towards fibrillar preparations of Aβ~42~, suggesting a synergistic action of tau and Aβ pathology on the mitochondria ([@b28-ndt-4-1033]).

In a follow-up study we investigated the toxicity of oligomeric Aβ species that in recent years have been suggested to be the main culprit, rather than fibrillar Aβ ([@b60-ndt-4-1033]; [@b92-ndt-4-1033]). The identity of the Aβ toxic species in both AD brains and in experimentally generated systems correlates best with the soluble, rather than the insoluble fibrillar forms. However, at present, there is little chemical and structural detail at the molecular and atomic level about the various aggregates to properly define the toxic species ([@b16-ndt-4-1033]). Interestingly, in cortical brain cells obtained from P301L tau transgenic pR5 mice both oligomeric and fibrillar, but not monomeric Aβ~42~ caused a decreased mitochondrial membrane potential ([@b36-ndt-4-1033]). This was not observed with cerebellar preparations indicating selective vulnerability of cortical neurons. Furthermore, we measured reductions in state 3 respiration, the respiratory control ratio and uncoupled respiration when incubating P301L tau mitochondria either with oligomeric or fibrillar preparations of Aβ~42~. We also found that aging specifically increased the sensitivity of mitochondria to oligomeric Aβ~42~ damage indicating that while oligomeric and fibrillar Aβ~42~ are both toxic, they exert different degrees of toxicity in mitochondria from older animals ([@b36-ndt-4-1033]).

To understand which processes are disrupted by Aβ~42~ in the presence of tau aggregates a comparative proteomics study was performed in both a cellular and an in vivo system ([@b29-ndt-4-1033]). P301L tau expressing neuroblastoma cells were treated with Aβ~42~ as prior studies had shown that this caused tau filament formation ([@b39-ndt-4-1033]; [@b97-ndt-4-1033]). In parallel, the amygdala of P301L tau transgenic mice was stereotaxically injected with Aβ~42~ as this causes increased tangle formation ([@b46-ndt-4-1033]). When the deregulated proteins in the two experimental paradigms were classified, it was found that a significant fraction of the altered proteins belonged to the same functional categories, ie, stress response and metabolism. We also identified model-specific effects of Aβ~42~ treatment such as differences in cell signaling proteins in the cellular model and changes in cytoskeletal and synapse proteins in the amygdala. By Western blotting and immunohistochemistry, we were able to show that 72% of the tested candidates were altered in human AD brain with a major emphasis on stress-related unfolded protein responsive candidates. This highlights these processes as important initiators in the Aβ~42~-mediated pathogenic cascade in AD and further supports the role of unfolded proteins in the course of AD ([@b29-ndt-4-1033]).

Human SH-SY5Y neuroblastoma cells were also investigated by transcriptomics to assess the role of P301L mutant tau expression and treatment with or without Aβ on gene regulation. We found that Aβ and P301L tau expression independently affected the regulation of genes controlling cell proliferation and synaptic elements. Moreover, Aβ and P301L tau acted synergistically on cell cycle and DNA damage genes, yet influenced specific genes within these categories. By using neuronally differentiated P301L tau cells, it was shown that Aβ treatment induced an early up-regulation of cell cycle control and synaptic genes. Together, the study showed that Aβ treatment and human tau over-expression in a cell culture model acted synergistically to promote aberrant cell cycle re-entry supporting the mitosis failure hypothesis in AD ([@b5-ndt-4-1033]; [@b62-ndt-4-1033]).

The Yin and Yang of Aβ
======================

AD has been termed a synaptic failure ([@b110-ndt-4-1033]). While Aβ can kill neurons, it can also act by causing synaptotoxicity which may be more relevant for the earlier stages of AD that are best characterized by synaptic loss rather than neuronal death. Loss of synaptic terminals or dendritic spines could cause the associated decline in cognitive functions that characterizes AD. Whether the neurotoxic and synaptotoxic actions of Aβ are separate activities or whether they share common mechanisms is not known ([@b16-ndt-4-1033]).

How cells respond to Aβ varies depending upon the concentration of Aβ used, which adds another level of complexity. While Aβ peptide added at micromolar concentrations to primary neuronal cultures induces cell death ([@b136-ndt-4-1033]), low, subnanomolar concentrations are neurotrophic arguing in favor of a physiological function of Aβ ([@b136-ndt-4-1033]). As discussed above, the neurotoxic activity of Aβ is dependent upon its aggregation state. When Aβ aggregation was induced this increased its neurotoxic activity suggesting that the toxic species was associated with the formation of fibrils ([@b102-ndt-4-1033]; [@b103-ndt-4-1033]; [@b101-ndt-4-1033]). At present, however, there is a major research focus on the role of non-fibrillar soluble Aβ as the toxic species in AD ([@b79-ndt-4-1033]; [@b126-ndt-4-1033]; [@b113-ndt-4-1033]). These species have been given different names, including Aβ-derived diffusible ligands (ADDLs) ([@b79-ndt-4-1033]). globulomers ([@b9-ndt-4-1033]) and the Aβ star species 56 (Aβ\*56) ([@b83-ndt-4-1033]). To assist in identifying these species, conformational antibodies have been developed that not only stabilize the Aβ protofibrils but also prevent mature amyloid fibril formation ([@b57-ndt-4-1033]).

Aβ can inhibit long-term potentiation (LTP), a model system for synaptic strengthening and memory ([@b79-ndt-4-1033]; [@b126-ndt-4-1033]; [@b23-ndt-4-1033]; [@b76-ndt-4-1033]; [@b123-ndt-4-1033]). When cell medium containing abundant Aβ monomers and proposed oligomers, but not amyloid fibrils was microinjected into rat brain, this markedly inhibits hippocampal long-term potentiation (LTP) ([@b126-ndt-4-1033]). Immunodepletion from the medium of all Aβ species completely abrogated this effect. Pretreatment of the medium with insulin-degrading enzyme, which degrades Aβ monomers but not oligomers, did not prevent the inhibition of LTP, indicating a role for Aβ oligomers. These were shown to disrupt synaptic plasticity in vivo at concentrations found in human brain and cerebrospinal fluid, in the absence of monomeric or fibrillar amyloid. When cells were treated with γ-secretase inhibitors at doses which prevented oligomer formation but allowed appreciable monomer production, this no longer disrupted LTP, indicating that synaptotoxic Aβ oligomers can be targeted therapeutically ([@b126-ndt-4-1033]; [@b127-ndt-4-1033]).

In Neuro-2A cells, oligomers were shown to induce a tenfold greater increase in neurotoxicity as compared to fibrils ([@b120-ndt-4-1033]). However, whereas LTP seems to be inhibited by oligomeric Aβ only and not fibrillar Aβ, in a different experimental paradigm, the two species seem to have both toxic, yet diverse effects ([@b132-ndt-4-1033]). Using rat astrocyte cultures, oligomeric Aβ~42~ was shown to induce initial high levels of the pro-inflammatory molecule IL-1β that decreased over time, whereas fibrillar Aβ caused increased levels over time ([@b132-ndt-4-1033]). It has been suggested that their neurotoxic activity is associated with dimeric and trimeric species however the exact composition of these higher molecular weight Aβ species has not been determined ([@b126-ndt-4-1033]; [@b23-ndt-4-1033]) and remains a crucial point to definitively establish their molecular identity. Together, this shows that the relative role of the toxicity of monomeric compared to oligomeric compared to fibrillar species is far from being resolved.

Aβ and downstream signaling
===========================

What are the down-stream effectors of Aβ toxicity? Aβ may act via a plethora of pathways to induce synaptic and neuronal degeneration ([@b112-ndt-4-1033]). Aβ's anti-LTP activity can be modulated with antagonists to the p38 MAP kinase ([@b128-ndt-4-1033]) and the Jun NH~2~-terminal kinase (JNK) pathways ([@b90-ndt-4-1033]), both of which have also been implicated in tau phosphorylation ([@b74-ndt-4-1033]; [@b75-ndt-4-1033]). While inhibitors of p38, JNK, GSK-3β and phosphatidylinositol 3-kinase showed either no or only minor inhibition of Aβ oligomer-mediated cell death in mouse hippocampal slices, inhibitors of MAPK kinase kinase, which is upstream of the extracellular signal-regulated kinases, significantly inhibited Aβ-mediated neuronal death ([@b22-ndt-4-1033]).

Another interesting kinase is the non-receptor tyrosine kinase Fyn, as it links Aβ and tau. Fyn is a known interaction partner of tau ([@b81-ndt-4-1033]). Furthermore, Fyn is necessary for the toxicity of ADDLs (an oligomeric form of Aβ) as Fyn knockout neurons are resistant to ADDL-mediated neuronal cell death ([@b79-ndt-4-1033]). Moreover, Fyn knockout mice display reduced synaptotoxicity without affecting aberrant sprouting, when crossed with APP transgenic mice ([@b21-ndt-4-1033]). Fyn has a role in modulating synaptic activity and plasticity, by phosphorylating the NMDA receptor ([@b15-ndt-4-1033]). This finding is consistent with the fact that Aβ oligomers alter the transport of the NMDA receptor by promoting its endocytosis and resulting in decreased NMDA receptor activity both in vitro and in APP transgenic mice ([@b115-ndt-4-1033]). Work in neuronal and astrocyte cultures further suggests that Aβ causes Ca^2+^-dependent oxidative stress by activating an astrocytic NADPH oxidase, with neuronal death following through a failure of antioxidant support ([@b1-ndt-4-1033]). Together, this suggests a fine-balanced network of molecular interactions ([@b16-ndt-4-1033]).

At present it is not understood whether Aβ acts via a receptor or whether membrane binding alone is sufficient ([@b16-ndt-4-1033]). If Aβ acts via a receptor, this receptor may have specificity for Aβ or it may bind proteins or peptides with shared amyloid properties. Work in primary cortical and hippocampal cultures treated with Aβ and human amylin, respectively, indicates that the latter may be the case, as rat amylin, which is not amyloidogenic, turns out not to be toxic ([@b85-ndt-4-1033]). Membrane interaction of Aβ can occur via its hydrophobic carboxy-terminal domain ([@b10-ndt-4-1033]; [@b2-ndt-4-1033]) or by electrostatic interactions mediated by the charged amino acids in the amino-terminal domain ([@b80-ndt-4-1033]). Aβ may bind to the cell membrane forming channels or pores that disrupt ion homeostasis, hence leading to neuronal dysfunction ([@b6-ndt-4-1033]; [@b104-ndt-4-1033]; [@b64-ndt-4-1033]; [@b10-ndt-4-1033]; [@b86-ndt-4-1033]). As several molecules associated with disease (such as the Prion protein, the British peptide, or human amylin) can form soluble oligomers and bind to membranes and disrupt ion homeostasis, this may be an inherent property of amyloidogenic proteins or peptides ([@b33-ndt-4-1033]).

Aβ binding proteins
===================

A number of Aβ-binding proteins have been identified on the plasma membrane of neurons and glial cells. These include the alpha7 nicotinic acetylcholine receptor, the receptor for advanced glycosylation end-products (RAGE), APP itself, the NMDA receptor, the P75 neurotrophin receptor (P75NTR), the scavenger receptors, CD36 and low-density lipoprotein receptor-related protein (LRP) members ([@b125-ndt-4-1033]). RAGE can bind both non-fibrillar and fibrillar forms of Aβ ([@b133-ndt-4-1033]). Transgenic mice co-expressing mutant APP and RAGE revealed an earlier onset of memory defects and synaptic dysfunction than single APP transgenic mice ([@b4-ndt-4-1033]). LRP, apoE and the serum protein α2-macroglobulin (α2M) probably modulate Aβ toxicity via clearance of apoE:Aβ and α2M:Aβ complexes or Aβ alone from the brain and hence reduce Aβ levels ([@b111-ndt-4-1033]; [@b31-ndt-4-1033]). The addition of an anti-NMDA receptor antibody can block Aβ oligomer binding to neurons and reduce ROS stimulation in hippocampal cultures ([@b30-ndt-4-1033]) suggesting a direct interaction between these two proteins. Alternatively, Aβ may be interacting with NMDA receptor via an integrin-mediated effect ([@b11-ndt-4-1033]). P75NTR can bind a variety of Aβ oligomeric species and modulate Aβ toxicity in a cell type- and P75 isoform-dependent manner ([@b24-ndt-4-1033]; [@b116-ndt-4-1033]). Full-length P75NTR blocks toxicity of fibrillar and non-fibrillar Aβ in primary neurons ([@b137-ndt-4-1033]), but promotes toxicity of fibrillar Aβ in neuroblastoma cells ([@b100-ndt-4-1033]).

Aβ may not only bind to the cell surface but also act on intracellular organelles such as mitochondria ([@b87-ndt-4-1033]; [@b18-ndt-4-1033]; [@b25-ndt-4-1033]; [@b35-ndt-4-1033]; [@b88-ndt-4-1033]) whose function it impairs ([@b73-ndt-4-1033]; [@b28-ndt-4-1033]; [@b36-ndt-4-1033]; [@b37-ndt-4-1033]). Mitochondrial dysfunction was also linked to full-length and carboxy-terminally truncated APP, that was shown to accumulate exclusively in the protein import channels of mitochondria of human AD, but not age-matched control brains ([@b35-ndt-4-1033]). Similarly, accumulation of full-length APP in the mitochondrial compartment in a trans-membrane-arrested form, but not lacking the acidic domain, was shown to cause mitochondrial dysfunction and impair energy metabolism ([@b3-ndt-4-1033]). Aβ can disrupt mitochondrial cytochrome *c* oxidase activity ([@b25-ndt-4-1033]; [@b122-ndt-4-1033]) in a sequence- and conformer-dependent manner ([@b25-ndt-4-1033]). The Aβ binding protein alcohol dehydrogenase (ABAD) is a short-chain alcohol dehydrogenase that binds to Aβ in the mitochondrial matrix. This lead to mitochondrial failure via changes in mitochondrial membrane permeability and a reduction in the activities of enzymes involved in mitochondrial respiration ([@b87-ndt-4-1033]). ABAD can bind to the oligomeric Aβ~42~ present in the cortical mitochondria of APP transgenic mice ([@b134-ndt-4-1033]). Protease sensitivity assays suggest that Aβ gains access to the mitochondrial matrix rather than simply being adsorbed to the external surface of mitochondria ([@b18-ndt-4-1033]). The interaction between Aβ and the mitochondria may explain how Aβ induces apoptosis and caspase activation ([@b70-ndt-4-1033]; [@b131-ndt-4-1033]; [@b87-ndt-4-1033]). Intracellullar Aβ may be derived from internalized extracellular Aβ or from intracellularly generated Aβ ([@b17-ndt-4-1033]; [@b43-ndt-4-1033]; [@b130-ndt-4-1033]). The presence of intracellular Aβ adds a further level of complexity to the mechanism of Aβ toxicity as this enables direct access to organelles that are vital for the function and viability of neurons. It is needless to say, that this has important implications for treatment strategies.

Conclusions
===========

What can be expected in the forthcoming years? Some of the current therapeutic trials targeting Aβ may come to fruition ([@b48-ndt-4-1033]). With the advent of new tools it will likely become easier to discriminate Aβ conformations and hence allow establishing a defined role of specific conformers in toxicity ([@b57-ndt-4-1033]). The mode of Aβ uptake and/or binding by neurons and other cell types will be elucidated and interacting proteins, both under physiologic and pathologic conditions, will be identified. Finally, how Aβ and tau interact and contribute to disease will assist in the development of treatment strategies for AD and related disorders.
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